NLS Pharmaceutics AG (NLSP) shares plunged 4.88% in after-hours on Tuesday, December 28, 2021, and closed the daily trading at $1.17. Even in the regular trading session, NLSP’s stock lost 1.60%. NLSP shares have moved down 6.82% in the past week. Over the past three months, the stock has lost 50.20%, while over the past six months, it has declined 61.20%.
Let’s discuss its recent news and developments.
Final results of NLSP NLS-4 (Lauflumide)
On November 30, 2021, NLS Pharmaceutics Ltd. (NLSP, NLSPW) reported final results from a preclinical study for NLS-4 (Lauflumide), the Company’s next-generation wake-promoting drug candidate. The Company believes that NLS-4 offers promise to become a foundational treatment for the chronic fatigue associated with the symptoms of Long-Covid and NLS-4 should improve recovery from CFS in humans at a dose that is four times lower than that used for modafinil.
Earlier on October 14, 2021, NLS Pharmaceutics Ltd. (NLSP, NLSPW) reported preclinical data for NLS-4 which showed promising results for the treatment of chronic fatigue associated with Long-COVID.
NLSP CEO letter to Shareholders
On November 1, 2021, CEO of NLS Pharmaceutics Ltd. (NLSP), Alex Zwyer, issued a letter to shareholders discussing the progress that NLS has made this year as they are advancing toward building a valuable company that serves patients suffering from rare and debilitating CNS disorders. The CEO said that they have moved swiftly into our Phase 2 clinical program for Quilience®, which is the lead product candidate for the treatment of narcolepsy.
Well, as of this writing, there is no recent news available which could be the reason behind its plummeting on Tuesday. We hope that it will return towards positivity in the coming trading sessions on Wednesday.
About the company
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company’s lead product candidate, Quilience®, is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy.